Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB +1.38%37 3-Year EPS without NRI Growth Rate is 16.80% as of Jun. 2026. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $35.48 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,160 Biotechnology companies, HCW Biologics ranks better than 50.86% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 16.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -5.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of HCW Biologics was 16.80% per year. The lowest was -51.10% per year. And the median was -8.00% per year.
HCW Biologics (NAS:HCWB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
HCW Biologics 3-Year EPS without NRI Growth Rate Related Terms
HCWB vs AAGH, ACXP, ENVB: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, HCW Biologics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where HCW Biologics's 3-Year EPS without NRI Growth Rate falls into.
HCW Biologics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 16.80% mean?
HCW Biologics (HCWB) has a 3-Year EPS without NRI Growth Rate of 16.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #570 out of 1160 companies in the Biotechnology industry, placing it in the top 49.1%.
Is HCW Biologics' 3-Year EPS without NRI Growth Rate too high?
HCW Biologics' current 3-Year EPS without NRI Growth Rate is 16.80%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. HCW Biologics' value of 16.80% is 5.3% above this industry median. Based on the distribution chart, HCW Biologics ranks #570 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' 3-Year EPS without NRI Growth Rate compare to AAGH and ACXP?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #570 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts HCW Biologics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. HCW Biologics' value of 16.80% is 5.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current 3-Year EPS without NRI Growth Rate of 16.80% is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for HCW Biologics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current 3-Year EPS without NRI Growth Rate is 16.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $35.48, compared to a current price of $2.94 — trading 91.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 16.80% and 5.3% above the Biotechnology industry median of 15.95. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For HCW Biologics (HCWB), the current 3-Year EPS without NRI Growth Rate is 16.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $2.94 is trading 91.7% below its estimated GF Value™ of $35.48.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
3-Year EPS without NRI Growth Rate: 16.80%
GF Value™: $35.48 vs. price of $2.94 (91.7% below fair value)
Industry Position: 5.3% above the Biotechnology median (#570 of 1160)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
